News & Events

View

Lucence secures US Medicare approval for its cancer tests

Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

22 February 2023

Lucence Shares Promising Interim Data from LIQUIK Prospective Study at ISLB 2022

23 October 2022

amplimark-2

Lucence and Omnigen Partner to bring Amplicon-based Liquid Biopsy Tests to Turkey

18 October 2022

Lucence Collaborates with National Cancer Centre Singapore to Launch Prospective Liquid Biopsy Study for Prostate Cancer

26 September 2022

Local Study Demonstrates Synergies of Using Blood-based Liquid Biopsies to complement Tissue Biopsies for Lung Cancer Diagnosis

Lucence Presents Data at 2022 World Conference on Lung Cancer (WCLC) Supporting Utility of Amplicon-Based Liquid Biopsy

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

1
2
3

Lucence secures approval for its Singapore-invented cancer tests from Medicare

>